Antenatal treatment of a mother bearing a fetus with congenital adrenal hyperplasia

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 82, Issue 3, 2000, Pages

  Brook, C G D ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE;

ADVERSE DRUG REACTION; AMNIOCENTESIS; CHORION VILLUS SAMPLING; CLINICAL PROTOCOL; CONGENITAL ADRENAL HYPERPLASIA; CORTICOSTEROID THERAPY; FETUS; HUMAN; PRENATAL CARE; PRIORITY JOURNAL; REVIEW;

EID: 0034105440     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.82.3.f176     Document Type: Review

References (22)

1. 1 Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987;316:178-82.
2. 2 Premawardhana LDKE, Hughes IA, Read GF, Scanlon MF. Longer term outcome in females with congenital adrenal hyperplasia: the Cardiff experience. Clin Endocr 1997;46:327-32.
3. 3 David M, Forest MG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 1984;105:799-801.
4. 4 Rumsby G, Massoud AF, Avey CJ, Brook CGD. Non-expression of a common mutation in the 21-hydroxylase gene: implications for prenatal diagnosis and carrier testing. J Med Genet 1996;33:708-9.
5. 5 Wedell A, Thilen A, Ritzen EM, Stengler B, Luthman H. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden; implications for genetic diagnosis and association with disease manifestations. J Clin Endocrinol Metab 1994;78:1145-52.
6. 6 Rumsby G, Avey CJ, Conway GS, Honour JW. Genotype-phenotype analysis in late-onset 21-hydroxylase deficiency in comparison to the classical form. Clin Endocrinol 1998;48:707-11.
7. 7 Day DJ, Speiser PW, Schultze E, et al. Identification of non-amplifying CYP21 genes when using PCR-based diagnosis of 21-hydroxylase deficiency in CAH affected pedigrees. Hum Mol Genet 1996;5:2039-48.
8. 8 Nimkarn S, Cerame BI, Wei J-Q, et al. Congenital adrenal hyperplasia without demonstrable genetic mutations. J Clin Endocrinol Metab 1999;84:378-81.
9. 9 Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
10. 10 Hindmarsh PC, Brook CGD. Single dose dexamethasone suppression test in children: dose relationship to body size. Clin Endocrinol (Oxf) 1985;23:67-70.
11. 11 Levine LS, Pang S. Prenatal diagnosis and treatment of congenital adrenal hyperplasia. J Pediatr Endocrinol 1994;7:193-200.
12. 12 Büscher MA, McClamrock HD, Adashi EY. Cushing's syndrome in pregnancy. Obstet Gynecol 1992;79:130-7.
13. 13 Jauniaux E, Rodeck C. Use, risks and complications of amniocentesis and chorionic villous sampling for prenatal diagnosis in early pregnancy. Biol Med 1995;1:245-52.
14. 14 Mercado AB, Wilson RC, Cheng KC, Ji-Qing Wei, New MI. Prenatal treatment and diagnosis of CAH owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1995;80:2014-20.
15. 15 Malunowicz EM, Ginalska-Malinowska M, Romer TE, Bal K. The influence of prenatal dexamethasone treatment on urinary excretion of adrenocortical steroids in newborns. Eur J Pediatr 1998;157:539-43.
16. 16 Quercia N, Chitayat D, Babul-Hirji R, Niw MI, Daneman D. Normal external genitalia in a female with classical CAH who was not treated during embryogenesis. Prenat Diagn 1998;18:83-5.
17. 17 Couper JJ, Hutson JM, Warne GL. Hydrometrocolpos following prenatal dexamethasone treatment for CAH. Eur J Pediatr 1993;152:9-11.
18. 18 Benediktsson R, Lindsay R, Noble J, Seckl JR, Edwards CRW. Glucocorticoid exposure in utero: a new model for adult hypertension. Lancet 1993;341:339-41.
19. 19 Barker DJP, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993;341:938-41.
20. 20 Lajic S, Wedell A, Bui T-H, Ritzen EM, Holst M. Long-term somatic follow-up of prenatally treated children with CAH. J Clin Endocrinol Metab 1998;83:3872-80.
21. 21 Seckl JR, Miller WL. How safe is long-term prenatal glucocortucoid treatment? JAMA 1997;277:1077-9.
22. 22 Kelnar CJH. CAH: the place for prenatal treatment and neonatal screening. Early Hum Dev 1993;35:81-90.